Ipilimumab

Generic Name: Ipilimumab

Brand Names: Yervoy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 477202-00-9

Unique Ingredient Identifier: 6T8C155666

Background: Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication: Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer

- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab

Associated Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)

Associated Therapies: First Line Chemotherapy

Clinical Trials

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Entinostat
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-06-11

Last Posted Date: 2022-01-12

Lead Sponsor: Roberto Pili

Target Recruit Count: 18

Registration Number: NCT03552380

Locations: 🇺🇸
Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Georgetown University, Washington, District of Columbia, United States

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Pembrolizumab
Procedure: Core Biopsy/Cryoablation
Procedure: Breast Surgery
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2018-06-06

Last Posted Date: 2024-07-24

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 80

Registration Number: NCT03546686

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Providence Cancer Institute, Portland, Oregon, United States

and more 1 locations

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Phase 1

Completed

Conditions: Metastatic Hormone-Sensitive Prostate Cancer

Interventions: Biological: PROSTVAC-V
Biological: PROSTVAC-F
Drug: Nivolumab
Drug: Ipilimumab
Biological: Neoantigen DNA vaccine
Device: TriGrid Delivery System
Procedure: Tumor biopsy
Procedure: Peripheral blood
Procedure: Fecal samples
Procedure: Leukapheresis

First Posted Date: 2018-05-22

Last Posted Date: 2022-08-05

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 19

Registration Number: NCT03532217

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma
Ocular Melanoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-05-17

Last Posted Date: 2023-04-11

Lead Sponsor: Suthee Rapisuwon

Target Recruit Count: 52

Registration Number: NCT03528408

Locations: 🇺🇸
Northwestern Univeristy Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Georgetown University, Washington, District of Columbia, United States

and more 3 locations

Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC

Phase 1

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Ipilimumab
Drug: SHR-1210

First Posted Date: 2018-05-17

Last Posted Date: 2018-05-30

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 10

Registration Number: NCT03527251

Locations: 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China

ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: CPI-1205
Drug: ipilimumab

First Posted Date: 2018-05-16

Last Posted Date: 2022-05-18

Lead Sponsor: Constellation Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT03525795

Locations: 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸
South Texas Oncology & Hematology, San Antonio, Texas, United States
🇺🇸
The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Phase 2

Recruiting

Conditions: Basal Cell Carcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Relatlimab

First Posted Date: 2018-05-11

Last Posted Date: 2024-03-22

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 57

Registration Number: NCT03521830

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Phase 2

Recruiting

Conditions: Bladder Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Procedure: Radical cystectomy

First Posted Date: 2018-05-09

Last Posted Date: 2024-10-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT03520491

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States

and more 4 locations